PFIZER2019-04-012019-06-30in-bse-fin:OneOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares PFIZER 2019-04-01 2020-03-31 2019-07-29 INR Crores First quarter Single segment Pharmaceuticals 2019-04-01 2019-06-30 Unaudited Standalone 5444000000.00 358300000.00 5802300000.00 805900000.00 863200000.00 241100000.00 876400000.00 21500000.00 250000000.00 995100000.00 4053200000.00 1749100000.00 0.00 1749100000.00 705100000.00 -84100000.00 621000000.00 0.00 1128100000.00 0.00 0.00 0.00 0.00 1128100000.00 -10900000.00 1117200000.00 0.00 0.00 457500000.00 10 24.66 24.66 0.00 0.00 24.66 24.66 NOTES: n n1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on August 09, 2019 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. n n2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016. n n3. The financial results for quarter ended June 30, 2019 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerindia.com n n4. The figures for the quarter ended March 31, 2019 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year. Also, the figures up to the end of the third quarter were only reviewed and not subjected to audit. n n5. Effective April 01, 2019 the Company adopted Ind AS 116 “Leases” using the modified retrospective method. Accordingly, comparatives for the year / quarter have not been retrospectively adjusted. The Right-of-Use asset is measured at an amount equal to the lease liability, adjusted by the amount of prepaid or accrued lease payments relating to the lease existing as on April 01, 2019. This resulted in recognition of Right-of-Use of asset Rs 123.03 crore and a Lease liability of Rs 98.13 crore. The effect of this adoption is not material on the profit for the period. n n6. The Company had entered into an agreement for sale of its business undertaking at Thane as a going concern, to Vidhi Research & Development LLP. The Company has received approval of the MIDC on July 03, 2019 for the transfer of the business undertaking including the land, plant & machinery and employees, save and except certain portion of the land which is subject to pending proceedings. n n7. The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made. n n n Other Expenses 995100000.00